Jerry Cade, MD

Medical Director
University Medical Center of Southern Nevada

Disclosure: Gilead (Individual(s) Involved: Self): Consultant, Research Grant or Support, Speakers' bureau; Janssen Pharmaceutica (Individual(s) Involved: Self): Consultant; Merck (Individual(s) Involved: Self): Consultant, Research Grant or Support, Speakers' bureau; ViiV Healthcare (Individual(s) Involved: Self): Consultant, Research Grant or Support

Presentation(s):

• 116 - Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study

  Oral Abstract